The endothelium is a favourite early target of cardiovascular risk factors and cardiovascular diseases like hypertension. This key role of the endothelium results from its capacity to respond to numerous autocrine and paracrine stimuli and to mechanical factors like shear stress but also from the pathophysiological consequences of endothelial dysfunction on vasomotor tone, arterial stiffness, arterial remodelling, and inflammation, all of which are factors that play a critical role in atherosclerosis and target-organ damage. In hypertension, endothelial dysfunction has been shown at the level of both resistance and conduit arteries and mainly results from an increase in nitric oxide (NO) degradation by interaction between NO and superoxide anions, while in experimental models of hypertension a decrease in NO production can also be observed. The fact that forearm endothelial dysfunction is a marker of future cardiovascular events in patients with hypertension stresses the importance of the clinical evaluation of endothelial function and of the evaluation of the effects of the different antihypertensive drug classes on this parameter. In this context, many studies have demonstrated that angiotensin-converting enzyme inhibitors, the perindopril-indapamide combination, and angiotensin II type I receptor (AT 1 ) blockers improve endothelium-dependent vasodilatation partly independently of arterial pressure. Both their antioxidant effects and the stimulation of the release of NO are involved in their beneficial effects. For calcium antagonists, only the recent drugs have been shown to improve endothelial function with a simultaneous improvement in several markers of oxidative stress. Finally, b-blockers classically do not affect endothelial function. Only nebivolol, a b-blocker with NO donor properties, has been shown to improve endothelial function, but this effect results from the increase in NO and not from the b-blocking properties of the drug.
Introduction
The endothelium is a favourite early target of cardiovascular risk factors and cardiovascular diseases like hypertension. This key role of the endothelium in terms of cardiovascular risk results from its capacity to respond to numerous autocrine and paracrine stimuli, because of the presence on these cells of numerous membrane receptors (eg muscarinic, serotoninergic, adrenergic, cytokines, growth factors, etc) or intracellular receptors (eg oestrogens) but also from its capacity to respond to various physiological stimuli such as pulsatile stress, shear stress forces exerted by blood flow, or oxygen partial pressure. These changes may in some cases be adaptive, but most often will result in an aggravation of the risk or of the disease, a situation that justifies targeting endothelial dysfunction for the treatment of hypertensive subjects.
Characterization of endothelial function
The endothelial dysfunction may be detected functionally as changes in vasomotor responses, cell proliferation, platelet adhesion/aggregation, vascular permeability, or leucocyte/endothelial interactions. Usually, experimental and clinical studies evaluate endothelial dysfunction as alterations of vasomotor function, and especially of endotheliumdependent relaxations.
In vitro, in isolated arteries, endothelium-dependent relaxations or dilatations are evaluated using agonists that are either receptor-dependent (acetylcholine, bradykinin, substance P, adenosine diphosphate (ADP), serotonin, histamine) or receptorindependent (calcium ionophore A23187), or by subjecting endothelial cells to physiological stimuli such as platelet aggregation, but also especially to shear stress forces exerted by intraluminal flow (flow-mediated vasodilatation). This latter stimulus is especially important, since shear stress represents the major physiological stimulus for the release of endothelial factors such as nitric oxide (NO).
The clinical exploration of endothelial function is achieved either by using circulating markers of endothelial function/integrity, or by use of functional tests, which directly study the endothelium of the resistance and/or conduit arteries of a given vascular territory.
Circulating markers include metabolites of NO (nitrites/nitrates), plasma levels of endothelin 1, markers of inflammation such as intercellular adhesion molecules, selectins, or markers of fibrinolysis such as tissue plasminogen activator and plasminogen activator inhibitor. Moreover, recent research on cell biology has identified novel and interesting circulating markers of endothelial function such as apoptotic microparticles of endothelial origin, circulating endothelial progenitors, and circulating endothelial cells.
Functional evaluation of endothelial function at the level of the microcirculation usually consists in studying the vasomotor effects associated with local administration of substances such as acetylcholine, and less frequently substance P or bradykinin, and to attribute the observed vasodilatory response to the release of NO, prostaglandin I 2 (PGI 2 ), or endothelium-derived hyperpolarizing factor (EDHF). The methods used for assessing these vasomotor responses depend on the vascular territories under investigation, but venous occlusion plethysmography and Doppler are most often used. At the level of large conductance arteries, endothelial function may be assessed invasively in coronary arteries (most often using quantitative angiography) or noninvasively in peripheral arteries using highprecision echo-tracking systems. In most studies evaluating endothelial function in large arteries, a common approach consists in assaying the changes in large artery diameter induced by distal arteriolar vasodilatation. Indeed, increases in blood flow induce proportional changes in artery diameter, and the extent of this 'flow-mediated vasodilatation' critically depends on the integrity of endothelial cells and on their capacity to produce NO and other endothelium-derived vasodilators. This technique has the advantage that it mimics a fundamental physiological process of NO production, that is, activation of endothelial NO synthase (eNOS) in response to changes in shear stress. The distal increase in flow may be induced by local administration of coronary vasodilators (eg in the coronary circulation), or consecutive to ischaemia (reactive hyperemia) or distal skin heating.
Hypertension and endothelial function
Experimental hypertension reduces endotheliumdependent relaxations both in large and small resistance arteries. This alteration is found in virtually all models of hypertension, including spontaneously hypertensive rats (SHR), 1 Goldblatt ('two-kidney one clip'), 2 deoxycorticosterone actetate (DOCA) salt or Dahl salt-sensitive rats. 3 This endothelial dysfunction is also found in human hypertension, especially at the level of resistance arteries, where it is characterized by a decreased forearm blood flow response to agonists such as acetylcholine or bradykinin, 4, 5 or by a decreased vasoconstrictor response to NO synthase inhibitors administered locally. 6 Endothelial dysfunction may also be detected in vitro in resistance artery segments isolated from hypertensive patients, where marked alterations in the vasodilatory responses to acetylcholine or flow may be detected.
Although endothelial dysfunction in hypertensive patients is well characterized at the arteriolar level, the data concerning large conduit arteries are more limited. However, several studies have demonstrated an alteration in flow-mediated vasodilatation of large epicardial coronary arteries in hypertensive patients. [7] [8] [9] The consequences of hypertension on the endothelium are not limited to changes in the endothelial regulation of vasomotor function. In particular, it is now well known that the endothelium may possess potent anti-inflammatory properties. Indeed, NO reduces (while superoxide anions increase) adhesion of leucocytes to the endothelium and limits expression of adhesion molecules such as intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), selectins, or expression of chemotactic factors such as monocyte chemoattractant protein 1 (MCP-1). [10] [11] [12] Thus, endothelial dysfunction in hypertension represents a likely trigger for an increased inflammatory response in the vascular wall. Since inflammation plays a pivotal role in all stages of atherosclerosis, it is likely that endothelial dysfunction is a critical event in the increased risk of atherosclerosis in hypertensive patients. This may partly explain the clinical data demonstrating that forearm endothelial dysfunction is a marker of future cardiovascular events in patients with essential hypertension. 13 
Mechanisms of dysfunction in hypertension
A large portion of the studies on endothelial dysfunction have concentrated on the mechanisms of the decreased bioavailability of NO. Schematically, this decrease may result either from a decrease in NO production or an increase in NO degradation. In hypertension, a decrease in the vascular effects of NO may be excluded, since the vasodilatory response to NO donors is usually maintained. The possible mechanisms of the changes in NO metabolism in hypertension are summarized in Figure 1 . They mainly result from decreased NO production or increased inactivation of NO.
Given the known mechanisms leading to NO production, decreased synthesis of this factor may result from (1) a deficiency in L-arginine, the substrate for NO synthase (NOS); 14 (2) the presence of a high concentration of endogenous inhibitors of NOS;
15-17 (3) a deficiency in cofactors for eNOS; 18, 19 (4) decreased eNOS expression by factors like hypoxia, tumour necrosis factor a (TNFa) or a decrease in flow and shear stress; and (5) an alteration of the transduction signals including phosphorylation of the enzyme or interactions with proteins like heat shock protein 90 (HSP90) or calmodulin and leading to activation of eNOS. Given the mechanisms of increased inactivation of NO, this inactivation results from binding to various molecules like haemoglobin or albumin, but the decrease in NO bioavailability is mostly the consequence of its interaction with superoxide anions, a phenomenon that is probably of importance in arterial hypertension. 20, 21 In physiological conditions, endogenous antioxidant systems limit these interactions and maintain an equilibrium between NO and O 2 À . However, this balance is altered in the presence of risk factors like diabetes and hyperlipidaemia, leading to an increased production of superoxide anions and a decrease in biologically active NO. This balance is also a fundamental event occurring in the context of diseases such as hypertension, since it may not only favour vasoconstriction, but also contribute to the associated increased leucocyte adhesion, local inflammatory processes, arterial remodelling, and increase in arterial stiffness.
Clinical studies have shown that essential hypertension is associated with an increase in production of oxygen-derived free radicals, 22 together with a decreased level of antioxidants. 23 The role of oxidative stress in hypertension-induced endothelial dysfunction in humans is also supported by data showing that vitamin C restores NO production and improves endothelial function in essential hypertension. 5 
Treatment of endothelial dysfunction in hypertension
Given the essential role of the endothelium in the control of vascular function, inflammation, thrombosis and proliferation, and considering the marked alterations in endothelial function in hypertension, it is clear that endothelial dysfunction has to be Several treatments of endothelial dysfunction have been tested in hypertension, and most have formed the basis of the hypotheses described above regarding the mechanisms of endothelial dysfunction. These include, for example, antioxidants, tetrahydrobiopterin (BH4), or L-arginine. However, at present, 'selective' treatments of endothelial dysfunction are still lacking. As a result of this, it is currently difficult to precisely define the possible links between endothelial dysfunction and hypertension or its effects on target organs such as the heart, brain or kidneys. However, the effects on endothelial dysfunction of various antihypertensive drugs have been tested even though it is generally difficult to distinguish between possible direct effects of these drugs on endothelial function from indirect protection secondary to the decreased blood pressure.
Renin-angiotensin system blockers
Many studies have demonstrated that angiotensinconverting enzyme (ACE) inhibitors improve endothelial function in hypertension. For example, in SHR, the ACE inhibitor cilazapril improves the endothelium-dependent relaxations to acetylcholine in the aorta. 24 A similar improvement is also found with the ACE inhibitor-diuretic combination perindopril-indapamide, which restores NO production and decreases the endothelium contractile responses in SHR aorta. [25] [26] [27] Interestingly, ACE inhibitors may also improve endothelial function in low-renin models such as Dahl rats, 28 despite the absence of a decrease in blood pressure, suggesting that the protective effect may be direct and not secondary to the reduction in hypertension.
Evidence for endothelial protection by blockers of the renin-angiotensin system also exists in humans. Indeed, in essential hypertension, ACE inhibitors and angiotensin II type I receptor (AT 1 ) blockers improve the basal release of NO and the coronary or forearm blood flow responses to acetylcholine, 7, 9, 29, 30 while ACE inhibitors or the perindopril-indapamide combination also improve flowmediated vasodilatation of brachial arteries.
As indicated above, angiotensin appears to play a central role in the development of oxidative stress and endothelial function in many situations, including hypertension. Thus, it seems logical that drugs interfering with the production or the effects of this peptide, that is, ACE inhibitors or angiotensin II AT 1 receptor antagonists should prevent these pro-oxidant effects and limit endothelial dysfunction as shown with the perindopril-indapamide combination. However, the effects of renin-angiotensin system blockers on endothelial dysfunction are not limited to these interactions with angiotensin II-induced oxidative stress. Indeed, the effects of ACE inhibitors involve potentiation of bradykinin, which is a potent stimulant for the endothelial release of NO, prostacyclin, and EDHF, while AT 1 receptor blockers may induce the release of NO secondary to stimulation of AT 2 receptors.
Calcium antagonists
Like ACE inhibitors, there is evidence that calcium channel blockers can improve endothelial function in experimental hypertension and in hypertensive patients. 8, 31 In one study, the improvement induced by the dihydropyridine lacidipine was not found with a b-blocker and was accompanied by improvements in several markers of oxidative stress. However, it seems that for a similar decrease in arterial pressure, calcium antagonists of the first generation like nifedipine are less effective than ACE inhibitors in terms of improvement in endothelial function. The exact mechanisms of the endothelial protective effects of calcium antagonists in hypertension are still largely unknown but could result from a prevention of oxidant stress.
b-Blockers
A number of studies show that endothelial function is not affected per se by this class of drugs. However, drugs like nebivolol, a selective b 1 -blocker with NO donor properties, has been shown to improve endothelial function in hypertensive subjects. 32, 33 Even if this effect clearly results from an increase in NO, this indicates that a b-blocker with specific vascular properties can have a beneficial effect on endothelial function.
In conclusion, the key role of endothelium in terms of cardiovascular risk in hypertensive subjects fully justifies its functional evaluation during hypertensive treatments and stresses the value of the fact that drugs like ACE inhibitors or the perindopril-indapamide combination markedly improve endothelial function.
